Microelectrode Array Assay for Botulinum Neurotoxin Potency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cell-based assays for detecting and quantifying botulinum neurotoxin (BoNT) potency are not sensitive enough and struggle to measure electrophysiological activity over multiple-day exposures, leading to difficulties in detecting potency and recovery after neurotoxin exposure.
Innovation Solution
A cell-based assay using microelectrode arrays (MEAs) that measures electrophysiological activity by exposing neuronal networks to varying dosages of BoNT, allowing for improved sensitivity and detection of neurotoxin potency through changes in electrophysiological responses, particularly at low concentrations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If microelectrode array (MEA) systems are used to measure electrophysiological activity, then the assay enables in vitro measurement of neuronal network responses, but the sensitivity is insufficient to detect potency differences at low BoNT concentrations
Solution Approach 1:
The patent segments the measurement process into multiple time points (baseline, post-exposure, and recovery phases) and uses multiple electrophysiological parameters (firing rate, burst frequency, synchronous activity). This segmentation allows detection of subtle potency differences that would be missed in a single measurement, thereby improving sensitivity while maintaining reliability
Solution Approach 2:
The patent adds temporal dimension by measuring electrophysiological activity over extended periods (multiple days) and across multiple time points. This transforms a static measurement into a dynamic, multi-dimensional assessment that captures the full response profile to BoNT exposure, enabling detection of potency differences at low concentrations
2Duration of action of moving object
If MEA networks are exposed to BoNT for multiple-day periods, then the assay can measure recovery of network activity, but a rapid decay in electrical activity occurs after exposure making measurement difficult
Solution Approach 1:
The patent establishes baseline electrophysiological measurements before BoNT exposure and implements controlled exposure protocols. This preliminary characterization of network activity allows accurate detection of changes during and after exposure, enabling measurement of recovery even when rapid decay occurs
Solution Approach 2:
The patent uses continuous monitoring of electrophysiological parameters during the exposure and recovery periods. This feedback allows real-time adjustment of measurement parameters and identification of optimal measurement windows, ensuring accurate measurement of recovery activity despite rapid decay
3Measurement precision
If the murine LD50-assay is used to assess BoNT potency, then accurate potency measurement is achieved, but animal testing is required which is costly and time-consuming
Solution Approach 1:
The patent creates an in vitro copy of the in vivo system by culturing neuronal networks on MEA chips that replicate key aspects of neuronal physiology. This cell-based model reproduces the electrophysiological responses to BoNT observed in live animals, providing accurate potency measurement without requiring animal testing
Solution Approach 2:
The patent replaces the mechanical/biological system of whole animal testing with an in vitro electrophysiological measurement system. By substituting animal-based assessment with MEA-based neuronal network measurement, the assay achieves comparable accuracy while dramatically improving throughput and reducing costs
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The assay demonstrates enhanced sensitivity in detecting BoNT potency, potentially replacing animal-based LD50 assays, reducing variability and costs, and enabling the measurement of therapeutic efficacy and safe dosage levels.
Implementation Method 1
Microelectrode array (MEA) systems enable a population of cells (known as a 'network') to be cultured on an array of extracellular electrodes, which record extracellular voltage changes that occur during the firing of action potentials (spikes) across the network
Data Source
AI summary
Methods for detecting and/or quantifying the potency of an agent using a cell-based assay are disclosed. A mammalian cell culture is grown upon a microelectrode array (MEA) which is used to measure an electrophysiological response of the mammalian cell culture. The cell culture is exposed to the agent, generally in at least two different dosages. The potency of the agent is detected by measuring a change in the electrophysiological responses associated with the at least two dosages when compared to a control condition. These changes can include the weighted mean firing rate (wMFR) and bursting of the cells.